user_id,prompt id,pmid_id,selection,annotation,outcome,comparator,intervention,invalid prompt,prompt reason
edin,82,2875419,Significantly increased,"Weight gain was higher for glargine (difference: 0.77 kg, P < 0.001).", Weight Gain , detemir , glargine ,0,
edin,17,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", cervical Bishop's score , placebo , antibiotic therapy ,0,
edin,75,3281242,Significantly increased,"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9?12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7?9.4; p < .0001) and through 24 weeks follow-up (Weeks 9?24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6?7.5; p < .0001).", continuous abstienence at 24 week follow up , placebo , varenicline ,0,
edin,64,1764008,No significant difference,Differences in the duration of the active-first and the second stages of labor were not statistically significant., duration of labor stages , epidural analgesia , Meperidine analgesia ,0,
edin,79,2875419,No significant difference,"The proportions of patients achieving A1C <7% were also similar (44.1 and 47.8%, respectively, P = 0.254), but significantly fewer glargine- than detemir-treated patients reached A1C <6.5% (16.5 and 22.7%, respectively, P = 0.017).",  number of patients with A1C <7%  ,  glargine  ,  detemir  ,0,
edin,13,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", neonatal outcomes , antibiotic therapy and tocolysis , tocolysis ,0,
edin,88,2944158,No significant difference,"IV therapy duration did not differ between groups (P = 0.22),", therapy duration , staff inclination replacement , routine replacement ,0,
edin,42,2674549,Significantly increased,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group, 55.1% (p?=?0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group. At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.", HAQ-DI score , placebo and methotrexate , 50mg of Golimumab and methotrexate ,0,
edin,51,524504,Significantly decreased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs. 22%, p < 0.05).", administration of oxytocin augmentation , dinoprostone , misoprostol ,0,
edin,43,2674549,Significantly increased,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group, 55.1% (p?=?0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group. At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.", HAQ-DI score , placebo and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,48,524504,Significantly increased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05),", number of women who deliver within 12 hours , dinoprostone , misoprostol ,0,
edin,77,3281242,Significantly increased,"Varenicline-treated subjects made their first quit attempt significantly earlier than placebo-treated subjects (p = .0074), with a median of 17 versus 24 days, respectively (Figure 2).", time to make first quit attempt , placebo , varenicline ,0,
edin,53,524504,No significant difference,"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs. 12%, p > 0.05).", abnormal fetal heart rate , misoprostol , dinoprostone ,0,
edin,60,524504,No significant difference,Hyperbilirubinemia 2	9 (11.3%)	5 (6.0%)	NS,  Hyperbilirubinemia  ,  misoprostol  ,  dinoprostone  ,0,
edin,70,1764008,No significant difference,There was no significant difference in the incidence of nausea and vomiting between the two groups (epidural 6% vs. meperidine 4%).,  nausea and vomiting  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,40,2674549,No significant difference,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group,", ACR20  , Golimumab 100 mg and placebo , placebo and methotrexate ,0,
edin,62,1764008,No significant difference,"There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.", rates of vacuum-assisted delivery rate , epidural analgesia , Meperidine analgesia ,0,
edin,95,2944158,Significantly increased,"For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001).,The maximum IVD dwell time was 1,023 hours (43 days) in the clinical replacement group, and this cannula was still working well on removal for completion of therapy.",  IVD dwell times  ,  routine replacement  ,  staff inclination replacement  ,0,
edin,39,2674549,Significantly increased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function., physical function , methotrexate , golimumab and methotrexate ,0,
edin,55,524504,No significant difference,Uterine Hyperstimulation	2 (2.5%)	1 (1.2%)	NS,  Uterine Hyperstimulation  ,  dinoprostone  ,  misoprostol  ,0,
edin,3,3298351,Significantly increased,The changes of ulceration area were statistically significant regardless of the type of compression therapy., venous ulcer healing , no treatment , compression therapy ,0,
edin,15,2366143,No significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.", gestational age , placebo , antibiotic therapy ,0,
edin,26,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  daily single iron tablets  ,0,
edin,30,3233526,No significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,  hemoglobin levels at week 28  ,  no treatment  ,  twice weekly single iron tablet  ,0,
edin,46,2674549,No significant difference,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group, 55.1% (p?=?0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group.,During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively.", serious adverse events , 50mg of Golimumab and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,93,2944158,No significant difference,"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43).",  infiltration  ,  staff inclination replacement  ,  routine replacement  ,0,
edin,81,2875419,No significant difference,Hypoglycemia risk was similar., Hypoglycemia , glargine , detemir ,0,
edin,34,3233526,Significantly increased,"There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks.,Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).", ferritin levels at week 28 , twice weekly single iron tablet , daily single iron tablets ,0,
edin,27,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  twice weekly single iron tablet  ,0,
edin,90,2944158,Significantly increased,"This review included six trials (n = 3,455) and reported no clinically important or statistically significant difference in catheter-related bloodstream infection or phlebitis between IVDs that were routinely resited (at 48-96 hours) or resited on clinical indication, yet there were significantly lower costs in the group resited on clinical indication",  cost per patient  ,  staff inclination replacement  ,  routine replacement  ,0,
edin,18,2366143,No significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.", white blood cell count , placebo , antibiotic therapy ,0,
edin,23,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., birth outcome , daily single iron tablets , weekly supplements of two iron tablets ,0,
edin,16,2366143,No significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.",  frequency of contractions  ,  placebo  ,  antibiotic therapy  ,0,
edin,56,524504,No significant difference,Meconium stained AF	15 (18.8%)	7 (9.6%)	NS,  Meconium stained AF  ,  misoprostol  ,  dinoprostone  ,0,
edin,54,524504,Significantly increased,"However, uterine tachysystole (p < 0.05)) and meconium stained amniotic fluid (p > 0.05) occurred more often in the misoprostol group as did abnormal heart rate tracing (22.5% vs.12%, p > 0.05) (Table 1).",  uterine tachysystole  ,  dinoprostone  ,  misoprostol  ,0,
edin,67,1764008,No significant difference,Active phase of first Stage of labor (h)	2.49 ± 1.40	2.40 ± 1.55	NS,  pain levels during first stage labor  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
edin,37,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L).", ferritin levels at week 38 , twice weekly single iron tablet , daily single iron tablets ,0,
edin,85,2944158,No significant difference,"IVD complication rates were 68 per 1,000 IVD days (clinically indicated) and 66 per 1,000 IVD days (routine replacement) (P = 0.86; HR 1.03; 95% CI, 0.74-1.43).", IVD comlication rates , staff inclination replacement , routine replacement ,0,
edin,76,3281242,No significant difference,"By the end of the quit window (Day 35), 391 (80.5%) varenicline subjects and 121 (73.3%) placebo subjects reported making a quit attempt (p = .062).",  frequency of quit events by day 35  ,  placebo  ,  varenicline  ,0,
edin,41,2674549,No significant difference,"At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.", Median HAQ-DI score , Golimumab 100 mg and placebo , placebo and methotrexate ,0,
edin,89,2944158,Significantly increased,"The overall number of IVDs per patient was significantly less (P = 0.004) for those replaced on clinical indication (mean 1.5, SD 0.8, median 1, quartiles 1 and 2) than for those routinely replaced (mean 1.8, SD 1.1, median 1, quartiles 1 and 2)",  frequency of replacements  ,  staff inclination replacement  ,  routine replacement  ,0,
edin,49,524504,Significantly increased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05),", number of women who deliver within 24 hours , dinoprostone , misoprostol ,0,
edin,58,524504,No significant difference,"More neonates in the misoprostol group had first minute Apgar scores lower than 7 (12.6% vs. 6.1%, p > 0.05), or needed neonatal resuscitation (11.4% vs. 9.9%, p > 0.05) but none of the babies had birth asphyxia,Neonatal resuscitation	9 (11.3%)	9 (10.8%)	NS",  Neonatal resuscitation  ,  misoprostol  ,  dinoprostone  ,0,
edin,96,2858204,Significantly increased,"In the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up in 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03).,n the per-protocol analysis, complete healing of the index ulcer occurred in 23/38 (61%) in the HBOT group and 10/37 (27%) in the placebo group (P = 0.009)",  frequency of healed index ucler after 1 year  ,  placebo  ,  HBOT   ,0,
edin,80,2875419,Significantly increased,"Improvements in A1C were ?1.46 ± 1.09% for glargine and ?1.54 ± 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017).", number of patients with A1C <6.5% , glargine , detemir ,0,
edin,91,2944158,No significant difference,"Resite on clinical indication would allow one in two patients to have a single cannula per course of IV treatment, as opposed to one in five patients managed with routine resite; overall complication rates appear similar.", IVD complications per person , staff inclination replacement , routine replacement ,0,
edin,44,2674549,No significant difference,"During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients", serious adverse events , placebo and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,22,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., birth outcome , weekly supplements of two iron tablets , twice weekly single iron tablet ,0,
edin,92,2944158,No significant difference,There were no local infections or IVD-related bloodstream infections in either group., phlebitis , staff inclination replacement , routine replacement ,0,
edin,65,1764008,No significant difference,"Oxytocin augmentation After initiation of Analgesia	197(100)	192(96)	NS,Administration of epidural analgesia with 1% lidocaine do not prolong the active-first or second stages of labor significantly, and do not increase the incidence of oxytocin augmentation",  oxytocin augmentation  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,4,3298351,No significant difference,"In all patients, independently of the type of compression therapy, a few significant statistical changes of ulceration area in time were observed (Student?s t test for matched pairs, p < 0.05). The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system ? on average 0.63 cm2/per week. The smallest loss of ulceration area was observed in patients using compression stockings ? on average 0.44 cm2/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).", venous ulcer healing , two-layer bandage , four-layer bandage ,0,
edin,74,3281242,Significantly increased,"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9?12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7?9.4; p < .0001)", continuous abstienence at week 12 , placebo , varenicline ,0,
edin,97,2858204,No significant difference,"Hypoglycemia (symptoms and blood-glucose <3.0 mmol/l) within 6 h after treatment occurred in two and four patients in the HBOT and placebo groups, respectively (n.s.).",  hypoglycemia occuring after treatment  ,  placebo  ,  HBOT   ,0,
edin,86,2944158,No significant difference,"Time to first complication per patient did not differ between groups (KM with log rank, P = 0.53).", time until first complication , staff inclination replacement , routine replacement ,0,
edin,71,1764008,No significant difference,"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.",  obstetric outcome  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,20,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., pregnancy , daily single iron tablets , weekly supplements of two iron tablets ,0,
edin,83,2875419,Significantly decreased,"Insulin doses, however, were significantly lower for glargine: 43.5 ± 29.0 versus 76.5 ± 50.5 units/day (P < 0.001),Moreover, trial data suggest that, although insulin doses are indeed higher in patients using detemir twice- versus once-daily, once-daily detemir doses are still higher than once-daily NPH and glargine doses (3,10,11). At present there is no clear explanation for the increased dose requirements for detemir",  frequency of insulin doses  ,  detemir  ,  glargine  ,0,
edin,2,3298351,No significant difference,"In all patients, independently of the type of compression therapy, a few significant statistical changes of ulceration area in time were observed (Student?s t test for matched pairs, p < 0.05). The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system ? on average 0.63 cm2/per week. The smallest loss of ulceration area was observed in patients using compression stockings ? on average 0.44 cm2/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).", venous ulcer healing , compression stocking , four-layer bandage ,0,
edin,66,1764008,No significant difference,"The preanalgesic visual analog pain scale scores were similar between the two study groups (epidural, 9 ± 1.2 vs. intravenous meperidine, 9 ± 1.3; P = 0.09).",  preanalgesic visual analog pain  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,29,3233526,No significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,  hemoglobin levels at week 28  ,  no treatment  ,  daily single iron tablets  ,0,
edin,45,2674549,No significant difference,"During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively.


Conclusion:", serious adverse events , Golimumab 100 mg and placebo , 100mg of Golimumab and methotrexate ,0,
edin,73,1764008,No significant difference,"As shown in table 4, infant outcome showed no evidence that the type of analgesia had any adverse effects on neonatal Apgar scores.",  neonatal outcome  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,10,3298351,No significant difference,"Table I
Comparable characteristics of patients treated with Maxis compression stockings and ProGuide two-layer and Profore four-layer compression systems,Ulceration area [cm2] (x ± SD)	4.7 ±4.18	5.3 ±3.93	6.0 ±3.98	p > 0.05,In the group of patients who used Maxis compression stockings complete healing was achieved in 8 (53.3%) ulcerations, in the groups of patients treated with layer compression systems, complete healing was achieved in 10 (62.5%) ulcerations treated with the two-layer compression system and 9 (60%) ulcerations treated with the four-layer compression system. The differences were statistically significant (p > 0.05).",  higher percentage of healed area  ,  Compression stocking  ,  layer compression  ,0,
edin,31,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L).", hemoglobin levels at week 38 , twice weekly single iron tablet , weekly supplements of two iron tablets ,0,
edin,9,3298351,Significantly increased,"However, greater dynamics of healing was observed in patients treated with the four-layer Profore system ? the average loss of area during the whole 12-week observation period was 0.63 cm2/per week.",  faster healing dynamics  ,  Compression stocking  ,  layer compression  ,0,
edin,63,1764008,No significant difference,"There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.", c-section , epidural analgesia , Meperidine analgesia ,0,
edin,38,2674549,Significantly decreased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function., symptoms of RA , methotrexate , golimumab and methotrexate ,0,
edin,84,2875419,Significantly decreased,"Detemir-treated patients had less weight gain and more often achieved A1C <6.5%, but the drop-out rate and daily insulin doses were lower in the glargine group.",  drop-out rate  ,  glargine  ,  detemir  ,0,
edin,94,2944158,No significant difference,"Occlusion, n (%)	5 (3%)	4 (2%)	RR 0.77 (0.21, 2.80), p = 0.75,There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43).",  occlusion  ,  staff inclination replacement  ,  routine replacement  ,0,
edin,87,2944158,No significant difference,There were no local infections or IVD-related bloodstream infections in either group., infections , staff inclination replacement , routine replacement ,0,
edin,7,3298351,No significant difference,"Initial CEAP score (x ± SD)	11.9 ±1.12	11.2 ±1.3	12.6 ±1.4	p > 0.05,The statistical analysis showed homogeneity of study groups in terms of age, sex, initial ulceration area and the initial value of CEAP; C-6 score.",  CEAP scores  ,  compression stocking  ,  two-layer bandage  ,0,
edin,5,3298351,No significant difference,"The statistical analysis showed homogeneity of study groups in terms of age, sex, initial ulceration area and the initial value of CEAP; C-6 score.,Initial CEAP score (x ± SD)	11.9 ±1.12	11.2 ±1.3	12.6 ±1.4	p > 0.05",  CEAP scores  ,  two-layer bandage  ,  four-layer bandage  ,0,
edin,33,3233526,Significantly increased,"There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks.,Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).", ferritin levels at week 28 , weekly supplements of two iron tablets , daily single iron tablets ,0,
edin,28,3233526,No significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,  hemoglobin levels at week 28  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
edin,19,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., pregnancy , weekly supplements of two iron tablets , twice weekly single iron tablet ,0,
edin,12,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", birth weight , antibiotic therapy and tocolysis , tocolysis ,0,
edin,24,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., birth outcome , twice weekly single iron tablet , daily single iron tablets ,0,
edin,35,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L).", ferritin levels at week 38 , twice weekly single iron tablet , weekly supplements of two iron tablets ,0,
edin,11,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", interval to delivery , antibiotic therapy and tocolysis , tocolysis ,0,
edin,72,1764008,No significant difference,"Women in both groups were similar in both obstetric and demographic characteristics,The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.",  obstetric intervention  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,36,3233526,No significant difference,"Group B, on the other hand, achieved significantly lower ferritin levels compared with Group A and Group C at 38 weeks,,Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).",  ferritin levels at week 38  ,  daily single iron tablets  ,  weekly supplements of two iron tablets  ,0,
edin,59,524504,No significant difference,The mean cord pH and the base deficit were comparable in the two groups.,  Core blood pH  ,  misoprostol  ,  dinoprostone  ,0,
edin,57,524504,No significant difference,Perinatal death	0	1(1.2%)	NS,  perinatal death  ,  misoprostol  ,  dinoprostone  ,0,
edin,61,524504,No significant difference,Birth trauma 3	0	2 (2.5%)	NS,  Birth trauma  ,  misoprostol  ,  dinoprostone  ,0,
edin,98,2858204,Significantly increased,"After two weeks of treatment, the reduction in ulcer area was doubled in the HBOT group (P = 0.037).",  downsizing of ucler area 2 weeks after treatment  ,  placebo  ,  HBOT   ,0,
edin,32,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L).", hemoglobin levels at week 38 , twice weekly single iron tablet , daily single iron tablets ,0,
edin,69,1764008,Significantly increased,Women who received epidural analgesia had a significantly higher incidence of hypotension compared with women who received intravenous meperidine (30% vs. 0; P < 0.0001).,  hypotension  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
edin,14,2366143,Significantly decreased,Women in the antibiotic group had a significantly lower incidence of postpartum infections compared with women in the placebo group., infection , placebo , antibiotic therapy ,0,
edin,21,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., pregnancy , twice weekly single iron tablet , daily single iron tablets ,0,
edin,8,3298351,No significant difference,"greater dynamics of healing was observed in patients treated with the four-layer Profore system ? the average loss of area during the whole 12-week observation period was 0.63 cm2/per week. The value of the same parameter in patients treated with the two-layer ProGuide compression system was 0.55 cm2/per week and of those treated with compression stockings 0.44 cm2/per week. Although the changes of ulceration area in each analysed group were statistically significant (p < 0.001), inter-group differences were not found (H = 4.45, p > 0.05).",  venous ulcer healing  ,  Profore compression  ,  ProGuide system  ,0,
edin,52,524504,No significant difference,"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05)", Caesarean section rate , misoprostol , dinoprostone ,0,
edin,78,2875419,No significant difference,"Improvements in A1C were ?1.46 ± 1.09% for glargine and ?1.54 ± 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017).", improved A1C , glargine , detemir ,0,
edin,50,524504,Significantly increased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05)", spontaneous rupture of membranes , dinoprostone , misoprostol ,0,
edin,68,1764008,Significantly decreased,"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 ± 3 vs. meperidine, 6 ± 4; P < 0.0001) and second stage (epidural, 4 ± 3 vs. meperidine, 8 ± 2; P < 0.0001) of labor.",  pain levels during second stage labor  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
edin,6,3298351,No significant difference,Initial CEAP score (x ± SD)	11.9 ±1.12	11.2 ±1.3	12.6 ±1.4	p > 0.05,  CEAP scores  ,  compression stocking  ,  four-layer bandage  ,0,
edin,25,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
edin,47,524504,Significantly decreased,"The induction-delivery interval was significantly lower in the misoprostol group than in the dinoprostone group (11.9 h vs. 15.5 h, p < 0.001).", induction-delivery interval , dinoprostone , misoprostol ,0,
edin,191,2517154,Significantly increased,"Over the whole observation period, the infliximab group had a slightly higher intake of pain killers (P < 0.01), and higher dysmenorrhea scores (P < 0.001 for physician assessment, for patient VAS scales and for patient diary).",  Dysmenorrhea scores  ,  Placebo  ,  Infliximab  ,0,
edin,159,2708184,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>",  6-minute walk test  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,128,2871176,Invalid Prompt,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,1, I don't have required information in abstract and I can't open the rest of article. I keep getting 404 page not found error 
edin,114,2871176,Significantly increased,"At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ? 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).",  Patients reaching HbA1c goals less than 7.0%   ,  Liraglutide (1.2 mg) plus glimepiride  ,  Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,211,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.,Forty patients undergoing coronary bypass surgery (n = 32) or aortic valve replacement (n = 8) were enrolled in this prospective, randomized, double-blind study. Two groups were formed. In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass. Group B served as a control with identical amounts of gelatin infusion (n = 20).", C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,179,2864284,Significantly decreased,<td></td><td></td><td></td><td></td>,  Pruritus  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,132,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02).,  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,134,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02).,  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.8 mg) plus glimepiride   ,0,
edin,103,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,143,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6?2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9?2.3 mmHg).",  Reductions in systolic blood pressure  ,  Rosiglitazone plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,188,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates. Routine pathology (FC) also showed no obvious differences between the two groups.",  Tissue examination by routine pathology  ,  Placebo  ,  Infliximab  ,0,
edin,163,2708184,No significant difference,"<td colspan=""8""><hr></td>",  Berg Balance Scale score  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,189,2517154,No significant difference,"After surgery, all pain estimates decreased to less than 10% of the baseline in both groups (Figs 1 and 2), and no differences were found between the placebo and the infliximab group (two-way analysis of variance).",  Pain estimates after surgery  ,  Placebo  ,  Infliximab  ,0,
edin,176,2864284,Significantly decreased,<td></td><td></td><td></td><td></td>,  Headache  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,178,2864284,No significant difference,<td></td><td></td><td></td><td></td>,  Parasitaemias associated with gametocytaemia  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,147,2871176,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ? 0.002).,  Pulse variations  ,  Placebo plus glimepiride  ,  Liraglutide (all doses) plus glimepiride  ,0,
edin,197,3187863,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25?1.69) and SU (37.9%; RR 1.45, 95% CI 1.22?1.73) (Table 2).",  Pain relief: Acupuncture  ,  Normal unit & Special unit  ,  Midwife-led unit  ,0,
edin,192,1852268,No significant difference,"In this study, ertapenem was as effective as piperacillin?tazobactam for the treatment of acute pelvic infection, was generally well tolerated, and had an overall safety profile similar to that of piperacillin?tazobactam.,The most common single pathogen was Escherichia coli . At the primary efficacy endpoint 2?4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin?tazobactam were cured (95% confidence interval for the difference, adjusting for strata, ?4% to 8.8%), indicating that cure rates for both treatment groups were equivalent.", obstetric/postpartum infection or gynecologic/postoperative infection ," Intravenous piperacillin?tazobactam, 3.375 g every 6 hours "," Inravenous ertapenem, 1 g once a day ",0,
edin,204,4106715,Significantly increased,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32?11.20).",  Prolonged abstinence from smoking rates to 12 months  ,  placebo  ,  high Ab group  ,0,
edin,164,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>",  Berg Balance Scale score  ,  Manually-assisted body-weight supported treadmill training (pre-test)  ,  Manually-assisted body-weight supported treadmill training (post-test)  ,0,
edin,121,2871176,Invalid Prompt,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,1, I get 404 not found error when I want to see the whole article 
edin,160,2708184,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>",  Late Life Function and Disability Instrument  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,201,2688140,No significant difference,"The duration of use of paralysing or sedative agents, mechanical ventilation, stay in the intensive care unit and mortality at 28 days did not differ significantly between the decremental PEEP titration and control groups."," The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents of patients with ARDS ", table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,130,2871176,Significantly decreased,"Although weight effects were modest, liraglutide produced more favourable weight effects compared with rosiglitazone, which produced substantial weight gain.",  Weight gain  ,  Liraglutide plus glimepiride  ,  Rosiglitazone plus glimepiride  ,0,
edin,135,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).",  HOMA-B  ,  Rosiglitazone plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,208,2206488,Significantly decreased,"In group A, lower peak (median) plasma levels of procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found.,n group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass. Group B served as a control with identical amounts of gelatin infusion (n = 20)."," Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I ", identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,169,2864284,Significantly increased,<td></td><td></td><td></td><td></td>,  Parasite clearance at day 2  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,137,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).",  HOMA-B  ,  Placebo plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,209,2206488,Significantly increased,"Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.,n group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass. Group B served as a control with identical amounts of gelatin infusion (n = 20).", Cardiac index  , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,120,2871176,Invalid Prompt,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,1, I got 404 Not Found error
edin,100,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d).",  HbA1c level at 26 weeks  ,  Rosiglitazone plus glimepiride  ,  Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,154,2871176,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26., Changes in calcitonin at week 26 , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,205,4106715,No significant difference,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32?11.20). The low Ab group did not differ significantly from placebo (7.1% vs. 6.0%, p=0.67).", Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
edin,156,2708184,No significant difference,"<td colspan=""8""><hr></td>", Paretic step length ratio , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
edin,198,3187863,No significant difference,"There were no significant differences in postpartum haemorrhage, sphincter injuries or in neonatal outcomes.", Postpartum haemorrhage , Normal unit & Special unit , Midwife-led unit ,0,
edin,112,2871176,Significantly increased,"At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ? 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,212,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", IL-6 (pg/ml) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,177,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Cure rate at day 28 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,155,2708184,No significant difference,"<td colspan=""8""><hr></td>", Self-selected overground walk velocity , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
edin,184,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Extend of the disease as visualized during surgery , Placebo , Infliximab ,0,
edin,117,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,119,2871176,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ? 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%)., ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,166,3001156,Significantly increased,"Increases were observed in self-referral of sick newborns for care, compliance after referral by the CHWs, and care-seeking from qualified providers and from the Kumudini Hospital, and decreases were observed in care-seeking from unqualified providers in the intervention arm.", Care-seeking from the Kumudini Hospital for ill newborns  , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,123,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,199,3187863,No significant difference,"Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth. An Apgar score <7 at 5 minutes was observed in 1.0, 1.4 and 0.4% of cases in the MU, NU and SU, respectively."," Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth ", Normal unit & Special unit , Midwife-led unit ,0,
edin,207,4106715,Significantly increased,"3?AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14?6.37).", attain 8 weeks continuous abstinence from weeks 19 through 26 , placebo group , recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) ,0,
edin,99,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d).", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,206,4106715,Significantly increased,"Statistically significant differences were observed in reduction of daily cigarette consumption and cotinine between non-abstainers (weeks 19?52) with high Ab levels and non-abstainers in the placebo group (p=0.0015 and 0.019, respectively; see Figures 4A and 4C.", Reduction of daily cigarette consumption and cotinine , non-abstainers in the placebo group , non-abstainers (weeks 19?52) with high Ab levels ,0,
edin,172,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Serious adverse events , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,107,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d).", HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,195,3187863,Significantly decreased,"Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59?0.89) and 38.0% in the SU (RR 0.69, 95% CI 0.56?0.86) (Table 2).", Oxytocin infusion for augmentation of labour , Normal unit & Special unit , Midwife-led unit ,0,
edin,182,2517154,No significant difference,No effect of treatment was found upon the mean diameters of the nodules as measured by TVU., Nodules diameters , Placebo , Infliximab ,0,
edin,202,4106715,Significantly increased,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53?12.71) with no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).", Prolonged abstinence from smoking rates to 6 months , placebo , high Ab group ,0,
edin,168,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Parasite clearance at day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,190,2517154,Significantly increased,"The strong and significant placebo effect and the absence of an infliximab effect were consistently found for all pain estimations in this study, i.e. the five scorings by the clinician and the calculated total scores (i.e. dysmenorrhea, deep dyspareunia, chronic pain, pelvic tenderness, the sum of the 3 BB pain scores and the total BB score) and the pain recorded in the dairy by the patients (i.e. the 3 BB scores, the visual analog scales, the pain killer intake and both calculated total scores, i.e. with or without taking pain killer intake into account).", Pain killers intake , Placebo , Infliximab ,0,
edin,194,3187863,Significantly decreased,"In the MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65?0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59?0.89) (Table 2).", Labour dystocia , Normal unit & Special unit , Midwife-led unit ,0,
edin,186,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Surgery duration , Placebo , Infliximab ,0,
edin,136,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).", HOMA-B , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,116,2871176,Significantly decreased,"By week 2, subjects treated with liraglutide had rapid and larger decreases in FPG vs. comparator treatment. At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001), while only liraglutide 1.2 or 1.8 mg produced greater reductions than rosiglitazone. FPG treatment differences to placebo were 1.7 mmol/l for liraglutide 0.6 mg and 2.6 mmol/l for both liraglutide 1.2 and 1.8 mg.", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,173,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Baseline white blood cell count , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,167,3001156,No significant difference,"At the time of the baseline household survey in January 2003, there was no significant difference between the intervention arm and the comparison arm of the study in the proportion of sick newborns who were taken outside the home for care from any qualified provider (including Kumudini Hospital), to the Kumudini Hospital specifically, or to an unqualified provider, most commonly an unlicensed ?village doctor?.", Care-seeking from unqualified providers (such as village doctors) for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,139,2871176,No significant difference,"There were no significant differences between treatments for HOMA-IR.

Table 2", HOMA-IR , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,213,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", IL-6r (ng/ml) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,110,2871176,Significantly increased,"The percentage of subjects reaching ADA [2] and International Diabetes Federation (IDF)/American Association of Clinical Endocrinologists (AACE) [11,12] treatment HbA1c goals with liraglutide was dose dependent (Fig. 4). At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ? 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,144,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6?2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9?2.3 mmHg).", Reductions in systolic blood pressure , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,165,3001156,No significant difference,Figure 2 demonstrates that there was a highly significant (p<0.00001) increase in the proportion of families that sought care from qualified providers for sick newborns in the intervention arm (Fig. 2 and Rows 5 and 7 of Table 2) and a non-significant increase in the comparison arm (Rows 5 and 8)., Care-seeking from qualified providers for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,109,2871176,Significantly decreased,"Rosiglitazone also was superior to placebo (P < 0.0001).,he greatest decreases occurred with liraglutide 1.2 and 1.8 mg (Fig. 3a?c). After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d). Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: ?1.4% (1.6, ?1.1); liraglutide 1.2 mg: ?1.3% (1.5, ?1.1); liraglutide 0.6 mg: ?0.8% (?1.1, ?0.6); rosiglitazone: ?0.7% (?0.9, ?0.4). All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001). Liraglutide 0.6 mg was non-inferior to rosiglitazone.", HbA1c level at 26 weeks , Placebo plus glimepiride , Rosiglitazone plus glimepiride ,0,
edin,106,2871176,Significantly decreased,"Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: ?1.4% (1.6, ?1.1); liraglutide 1.2 mg: ?1.3% (1.5, ?1.1); liraglutide 0.6 mg: ?0.8% (?1.1, ?0.6); rosiglitazone: ?0.7% (?0.9, ?0.4). All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001).", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,149,2871176,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ? 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01)., Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,104,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,180,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Haemoglobin concentration , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,111,2871176,Significantly increased,"The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).

FIGURE 4", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,187,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Bleeding during surgery , Placebo , Infliximab ,0,
edin,157,2708184,No significant difference,"<td colspan=""8""><hr></td>", Locomotor-training effects , Slow treadmill speed , Fast treadmill speed ,0,
edin,122,2871176,Significantly increased,"The percentage of subjects achieving FPG values between 5.0 mmol/l and ? 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%).,The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).", ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,126,2871176,Significantly increased,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,158,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Self-selected overground walk velocity , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,125,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,183,2517154,No significant difference,"Endometrial thickness was not affected by treatment, being at baseline and at the end of the treatment period for the infliximab group 5.2 (range 1.3?18) and 7.8 (1.9?11) mm and for the placebo group 7.7 (1.8?23) and 8.2 (3?15) mm, respectively.", Endometrial thickness , Placebo , Infliximab ,0,
edin,175,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Fever resolution by day 2 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,133,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02)., Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,171,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Superiority of treatment given by survival curves , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,146,2871176,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7?1.4 mmHg), with no significant differences between treatments.", Decreases in diastolic blood pressure , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,127,2871176,Significantly increased,"he percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,174,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Fever resolution by day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,118,2871176,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ? 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%)., ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,185,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Macroscopic aspect of the tissue , Placebo , Infliximab ,0,
edin,142,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6?2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9?2.3 mmHg).", Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,162,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Physical performance battery scores , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,129,2871176,No significant difference,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,131,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02)., Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,140,2871176,No significant difference,There were no significant differences between treatments for HOMA-IR., HOMA-IR , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,203,4106715,No significant difference,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53?12.71) with no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).", Prolonged abstinence from smoking rates to 6 months , placebo , low Ab group ,0,
edin,170,2864284,Significantly decreased,<td></td><td></td><td></td><td></td>, Recurrent infections at day 56 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,150,2871176,No significant difference,"Main adverse events for all treatments were minor hypoglycaemia (< 10%), nausea (< 11%), vomiting (< 5%) and diarrhoea (< 8%).", Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,124,2871176,Significantly decreased,reatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5?2.4 mmol/l; P < 0.0001) and greater with liraglutide 1.2 mg (0.64 mmol/l; P = 0.043) and 1.8 mg (0.87 mmol/l;P = 0.0022) compared with rosiglitazone., Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,113,2871176,Significantly increased,"he estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,145,2871176,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7?1.4 mmHg), with no significant differences between treatments.", Decreases in diastolic blood pressure , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,161,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Improvement in lower extremity Fugl-Meyer score  , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,102,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,101,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,108,2871176,No significant difference,"All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001). Liraglutide 0.6 mg was non-inferior to rosiglitazone.", HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,181,2517154,No significant difference,"Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001). However, no effect of infliximab was observed for any of the outcome measures.", Severity of pain , Placebo , Infliximab ,0,
edin,141,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6?2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9?2.3 mmHg).", Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,153,2871176,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26., Changes in calcitonin at week 26 , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,210,2206488,Significantly decreased,"Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.,In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass.", systemic vascular resistance , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,196,3187863,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11?1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16?2.13).", Pain relief: Epidural anesthesia , Normal unit & Special unit , Midwife-led unit ,0,
edin,115,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,193,3187863,No significant difference,There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2)., Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit & Special unit , Special unit ,0,
edin,200,2688140,No significant difference,"The overall mortality at 28 days was 37%. Mortality at 28 days was 33% in the control group and 40% in the decremental PEEP titration group (Table 2). Using Cox regression for 28-day mortality, the survival rate in the decremental PEEP titration group was not different (p = 0.725; hazard ratio = 1.168; 95% confidence interval = 0.493 to 2.768).", The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,138,2871176,No significant difference,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).", HOMA-B , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,148,2871176,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ? 0.002), Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,152,2871176,Significantly increased,"Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.", Incidence of minor hypoglycaemia , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,151,2871176,Significantly increased,"Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.", Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,105,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d).", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,400,2690844,No significant difference,Postoperative complications (Table 4) were seen in 16 out of 75 patients (21%) from the midline incision group and in 15% from the transverse incision group (11 patients) (P = 0.30), Complications after surgery , Midline incision , Transverse incision ,0,
edin,442,2600646,Significantly decreased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,376,3580134,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 ?g (p ? 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 ?g (p ? 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score (table IV). Table III", Awakening-free nights percentage improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,472,2847809,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">Death events</td><td align=""center"" colspan=""1"" rowspan=""1"">4 (4.3)</td><td align=""center"" colspan=""1"" rowspan=""1"">2 (2.1)</td><td align=""center"" colspan=""1"" rowspan=""1"">2 (2.1)</td><td align=""center"" colspan=""1"" rowspan=""1"">0.47</td>", Complications and mortality , Placebo , Clopidogrel ,0,
edin,344,3580134,Significantly increased,Time to first COPD exacerbation was significantly prolonged with both budesonide/formoterol dosages compared with placebo (p ? 0.004) and with budesonide/formoterol 320/9 ?g compared with formoterol (p = 0.026) [figure 6]., Time to first COPD exacerbation , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,474,2847809,Significantly decreased,The primary AVF failures at two months were 21.6% in placebo group and 5.2% in clopidogrel group (P = 0.03)., The primary arteriovenous fistula failures at two months , Placebo , Clopidogrel ,0,
edin,315,3580134,Significantly increased,"Although improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 ?g also resulted in significantly greater improvements compared with formoterol (p = 0.023) [figure 3b].", 1-hour post-dose FEV1 improvements , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,279,2375236,Significantly decreased,"Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.", Information recall , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,480,2447617,Significantly increased,"<td align=""left"">6 months</td><td></td><td></td>", The analysis using the dichotomization of GOS scores at 6 months post injury , placebo , progesterone ,0,
edin,324,3580134,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ? 0.002) [table II]., Mean FEV1 at 12 hours at end of treatment , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,406,2690844,Significantly decreased,The mean width of the scar after the healing of the midline incisions was found to be 8.3 ± 1.4 mm. The mean width of the scar after the healing of the transverse incisions was measured to be 3.3 ± 1.2 mm. This observed difference is significant (P < 0.0001)., Scar width , Midline incision , Transverse incision ,0,
edin,481,2899760,Significantly increased,"Fusion rate in the SR group was 92%, and in the TM group 69% (P < 0.05).", Fusion rate , anterior cervical decompression and fusion (ACDF) with Trabecular Metal? (TM) , raditional Smith?Robinson (SR) procedure with autograft  ,0,
edin,224,1475568,Significantly decreased,"The control group did have statistically significantly higher baseline MLHF scores representing worse symptoms at baseline.,Patients enrolled in the control group received a general heart failure education pamphlet written at approximately the 7th grade level, and continued with usual care from their primary physician.", Minnesota living with heart failure (MLHF) questionnaire baseline scores , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,374,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].,Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 ?g (p ? 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 ?g (p ? 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score (table IV). Table III", Sleep score improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,319,3580134,Significantly increased,Morning and evening PEF improved significantly for all active treatments compared with placebo (p ? 0.012), Peak expiratory flow in the morning and evening  , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,440,2600646,No significant difference,"<td colspan=""8""><hr></td>", mean Hb , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,268,2691927,Significantly decreased,Differences regarding postoperative dosage of opiates and the visual analog scale (VAS) for pain scoring system were in favor of the laparoscopic procedure., Need for opiates , Conventional open approach , Laparoscopic surgery ,0,
edin,286,1871574,Significantly increased,"<td></td><td colspan=""5""><hr></td>", Quit attempt of 1 week or longer reported at 3 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,309,2817867,Significantly increased,Sixty percent of patients suffered local recurrences after RFA compared to 7% after hepatic resection., Local recurrence rate through the study , Hepatic resection , Radiofrequency ablation ,0,
edin,241,3090298,No significant difference,"Total root-mean square (RMS) HOAs, coma, trefoil, and spherical aberrations are compared in Figure 2. There were no significant differences between groups in any HOAs throughout the study (P ? 0.101), with all P values at 6 months ?0.63.", Higher-order aberrations during the study , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,216,1475568,No significant difference,"In unadjusted analysis, the control group, on average, improved 5 points on the MLHF and the intervention group improved by 1 point. The difference was not statistically significant (3.5 points, 95% CI 11, -4, p = 0.36). After adjusting for baseline differences between the groups, the difference was 2 points (95% CI 9, -5, p = 0.59) suggesting no effect on heart failure-related quality of life.", Heart failure-related quality of life at the end of treatment , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,307,2817867,Significantly decreased,"The 5-year overall survival after resection alone was 43% (95% CI = 26 to 58%), while the 5-year survival after RFA alone was 23% (95% CI = 11 to 39%), as shown in Figure 1. This difference was statistically significant (P = .02).", Overall survival rate at 5 years , Hepatic resection , Radiofrequency ablation ,0,
edin,432,3187863,Significantly increased,"There were statistically significant differences in augmentation (midwife-led unit versus normal unit RR 0.73, 95% CI 0.59?0.89; midwife-led unit versus special unit RR 0.69, 95% CI 0.56?0.86), in epidural analgesia (midwife-led unit versus normal unit RR 0.68, 95% CI 0.52?0.90; midwife-led unit versus special unit RR 0.64, 95% CI 0.47?0.86) and in acupuncture (midwife-led unit versus normal unit RR 1.45, 95% CI 1.25?1.69; midwife-led unit versus special unit RR 1.45, 95% CI 1.22?1.73).", Pain relief: Acupuncture , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,302,2817867,Significantly decreased,Operative blood loss (median 1400?mL (range 100 to 9000) versus 150?mL (range 50 to 2300); P < .0005) and transfusion requirements (44% of patients versus 5%; P < .0005) were higher for resection than for RFA., Blood loss during surgery , Hepatic resection , Radiofrequency ablation ,0,
edin,326,3580134,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ? 0.002) [table II]., Baseline-adjusted average 12-hour FEV1 at end of treatment , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,443,1468428,No significant difference,"We found no significant differences in puerperal or neonatal infection rates (Puerperal infection: 41/190 [22%] with enema v 26/182 [14%] without enema; RR 0.66 CI 95%: 0.43 to 1.03; neonatal infection 38/191 [20%] with enema v 40/179 [22%] without enema; RR 1.12, 95% CI 95% 0.76 to 1.66),", Puerperal and neonatal infection rates  , no enema , 1 litre saline enema ,0,
edin,341,3580134,Significantly increased,"Improvements from baseline to the average over the randomized treatment period in 1-hour post-dose IC were significantly greater with both budesonide/formoterol dosages compared with placebo (p < 0.001) and formoterol (p ? 0.018) [figure 5b].,Both dosages of budesonide/formoterol resulted in a 350 mL (?25%) improvement from baseline to the average over the randomized treatment period in 1-hour post-dose IC, and formoterol resulted in a 210 mL (17%) improvement in 1-hour post-dose IC. Fig. 5", 1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,403,2690844,No significant difference,"Surgical site infections were diagnosed in 7 and 3 patients, respectively (P = 0.33).Table 4", Infection of the surgical site , Midline incision , Transverse incision ,0,
edin,347,3580134,Significantly decreased,"In addition, significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 ?g and 160/9 ?g versus placebo (37% and 41%, respectively; p < 0.001) and formoterol (25% and 29%, respectively; p ? 0.004) [see figure S2 in the supplementary material].", Amount of exacerbations per patient-treatment year , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,231,3090298,Significantly decreased,"Statistically significant differences were found between PRK and thin-flap LASIK in UDVA at 1 month postoperatively, with thin-flap LASIK eyes showing more improvement in UDVA.", Uncorrected distance visual acuity at 1 month , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,389,2690844,Significantly increased,"The length of the incisions was 140 ± 24 mm and 164 ± 28 mm for the transverse and the midline incisions, respectively. The difference in scar length was found to be significant (P < 0.0001).", Smaller incision  , Midline incision , Transverse incision ,0,
edin,482,2899760,No significant difference,There was no statistically significant difference in clinical outcomes between fusion techniques or between patients who appeared radiologically fused or non-fused., clinical outcomes , anterior cervical decompression and fusion (ACDF) with Trabecular Metal? (TM) , raditional Smith?Robinson (SR) procedure with autograft  ,0,
edin,367,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Overall use of daily rescue medication improvement , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,402,2690844,No significant difference,"Briefly, one patient in each group developed cardiac complications; 8 and 6 patients developed urinary retention after the midline and transverse incisions, respectively (P = 0.59).", Urinary retention , Midline incision , Transverse incision ,0,
edin,283,2361806,No significant difference,"For ILF and ELF, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542), and overall survival was 10.8 vs 8.3 months (P=0.2818).", Overall survival , Etoposide with 5-fluorouracil plus leucovorin (ELF) , Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF) ,0,
edin,397,2690844,No significant difference,Staff surgeons performed 17% (13/75 patients) of all procedures performed through a midline incision. The remainder of the procedures through a midline incision was carried out under staff surgeon supervision. Staff surgeons performed 14% of all procedures in the transverse incisions study group (10/74 patients) and supervised the remainder. No statistically significant difference was found between the two randomised groups (P = 0.65)., Procedure performed directly by the staff surgeon , Midline incision , Transverse incision ,0,
edin,233,3090298,No significant difference,Visual acuities were not statistically different between the groups at 3 or 6 months., Corrected distance visual acuity at 6 months , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,254,1831737,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.", Patients infected with T. vaginalis , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,282,2361806,No significant difference,"For ILF and ELF, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542), and overall survival was 10.8 vs 8.3 months (P=0.2818).", Time to treatment failure , Etoposide with 5-fluorouracil plus leucovorin (ELF) , Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF) ,0,
edin,447,2607225,Significantly increased,"Individual support patients had a higher level of cognitive functioning (mean=87.4, s.d.=14.2) as compared with non-IS patients (mean=84.0, s.d.=16.4) (F=4.6, d.f.=1/321, P=0.046) from 3 to 24 months.", cognitive functioning , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,385,2721929,Significantly increased,"Mean urgency score decreased by 44.8%, 62.2% and 60.2% in the BT, To, and Co groups, respectively, and the improvement was significantly greater in the To and Co groups than in the BT group (p<0.05 for each).", Urgency score improvement , Bladder training only (BT) , Bladder training plus tolterodine (Co) ,0,
edin,467,3387601,Significantly increased,"There was a negative correlation between CSF protein and duration of mechanical ventilation in the PE group (p = 0.037), but not in the IVIG group (p = 0.132).", negative correlation between CSF protein and duration of mechanical ventilation , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,305,2817867,No significant difference,"Rates of ICU admission (6.5% of patients overall), and length of stay (median of 7 days for all patients; range 1 to 48) were not significantly different between patients having hepatic resection and RFA.", Hospital stay , Hepatic resection , Radiofrequency ablation ,0,
edin,273,2691927,No significant difference,"Nasogastric decompression could be stopped after 2?3 days in both groups (Table 4).Table 4,<td align=""left"">Median duration of nasogastric decompression (days) + IQR</td><td align=""char"" char=""("">2.0 (3.0)</td><td align=""char"" char=""("">3.0 (1.3)</td><td align=""char"" char=""."">0.334</td>", Time to nasogastric decompression , Conventional open approach , Laparoscopic surgery ,0,
edin,456,3446002,No significant difference,On serial daily examination during phototherapy and up to 2 days after that no problems or side effects were observed., side effects , control group , single dose of 50 mg/kg clofibrate ,0,
edin,269,2691927,No significant difference,"Time to discharge was similar for the two groups, with a median difference of 1.5 days (Table 4),<td align=""left"">Median hospital stay (days) + IQR</td><td align=""char"" char=""("">6.5 (9.3)</td><td align=""char"" char=""("">8.0 (7.3)</td><td align=""char"" char=""."">0.235</td>", Hospital permanence , Conventional open approach , Laparoscopic surgery ,0,
edin,463,1876597,No significant difference,Both drugs were well tolerated; serious adverse events were uncommon and unrelated to study drugs., Adverse Events , artemether-lumefantrine , dihydroartemisinin-piperaquine  ,0,
edin,238,3090298,No significant difference,"At 6 months contrast sensitivity in the PRK group was still significantly decreased from baseline at 3 cpd (P = 0.013), although it did not reach a statistically significant difference at 3 months (P = 0.101).", Contrast sensitivity at 3 months seen at 3 cpd , Pre-surgery baseline , Photo-refractive keratectomy (PRK) ,0,
edin,265,2691927,Significantly decreased,"The VAS score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.", Visual analog scale pain score at day 3 , Conventional open approach , Laparoscopic surgery ,0,
edin,395,2690844,No significant difference,"Furthermore, no differences were found in the body mass and average length between the two groups (Table 1).", Average patient's weight , Midline incision , Transverse incision ,0,
edin,264,2691927,Significantly decreased,"he VAS score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.", Visual analog scale pain score at day 1 , Conventional open approach , Laparoscopic surgery ,0,
edin,278,2375236,Significantly decreased,"Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.", Anxiety , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,370,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Cough score improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,479,2447617,Significantly increased,"<td align=""left"">6 months</td><td></td><td></td>", The analysis using the dichotomization of GOS scores at 3 months post injury , placebo , progesterone ,0,
edin,261,1831737,Significantly increased,"In the general population sample interviewed in the follow-up survey, 1,779 (35%) and 647 (13%) of 5,098 respondents reported attending an HIV/AIDS meeting and a programme meeting, respectively (Table 5). More respondents in the intervention communities than in the control communities attended an HIV/AIDS meeting (41% versus 28%, prevalence rate ratio 1.44 [95% CI 1.33?1.56], p < 0.001) and a programme meeting (20% versus 5%, 4.27 [95% CI 3.52?5.17], p < 0.001),", Programme meeting attendance , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,387,2721929,No significant difference,"No difference was observed between the To and Co groups.,When we compared these changes among the three groups, we found that patients in the Co group showed greater improvements in frequency and urgency scores than did patients in the BT group (p<0.05 each), and that urgency scores in the To and Co groups showed significantly greater improvement than in the BT group (p=0.017 and p=0.021, respectively).", Urgency score improvement , Tolterodine only (To) , Bladder training plus tolterodine (Co) ,0,
edin,276,2375236,Significantly increased,Patients provided with a question prompt sheet asked more questions about prognosis compared with controls and oncologists gave significantly more prognostic information to these patients., Prognosis information given , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,237,3090298,Significantly decreased,"The thin-flap LASIK group showed no change in contrast sensitivity postoperatively (P > 0.131), while patients in the PRK group had a slight decrease in contrast sensitivity at 1 month seen at 3 and 12 cpd (P = 0.004) and (P = 0.025), respectively", Contrast sensitivity at 1 month seen at 3 cpd , Pre-surgery baseline , Photo-refractive keratectomy (PRK) ,0,
edin,298,1871574,Significantly increased,"<td></td><td colspan=""5""><hr></td>", Smoking cessation at 6 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,428,3187863,No significant difference,There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2)., Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit &amp; Special unit , Special unit ,0,
edin,292,1871574,No significant difference,"<td></td><td colspan=""5""><hr></td>,<td></td><td colspan=""5""><hr></td>", Baseline cotinine level , Usual care , Smoking cessation advice and NRT offered ,0,
edin,423,1187893,Significantly increased,"<td colspan=""7""><hr></td>", Knee injury and Osteoarthritis Outcome Score quality of life subscale at 6 months , No exercise , Exercise ,0,
edin,323,3580134,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ? 0.002) [table II]., Mean FEV1 at 12 hours on the day of randomization , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,295,1871574,Significantly increased,"<td></td><td colspan=""5""><hr></td>", Smoking reduction at 3 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,316,3580134,Significantly increased,"lthough improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 ?g also resulted in significantly greater improvements compared with formoterol (p = 0.023) [figure 3b].", 1-hour post-dose FEV1 improvements , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,217,1475568,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men.,Regardless of these differences, none were statistically significant.", Baseline hypertension , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,258,1831737,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.", Intake of STI treatment , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,448,2607225,Significantly decreased,"Appetite loss decreased from 3 to 6 months (mean=5.1?3.7, s.d.=14.2?11.1), worsened at 12 months (mean=5.8, s.d.=16.0) and decreased again at 24 months (mean=4.1, s.d.=12.7) in GR patients, whereas it improved from 3 to 6 and 12 months (mean=8.1, 4.0, 2.4; s.d.=17.7, 12.6, 10.8) and worsened at 24 months (mean=2.8, s.d.=10.7) in non-GR patients (F=4.1, d.f.=3/963, P=0.007).", Appetite loss , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,441,2600646,No significant difference,"<td colspan=""8""><hr></td>", Adverse events , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,377,3580134,Significantly decreased,The geometric mean values of 24-hour urinary cortisol at 6 months and end of treatment were lower in both budesonide/formoterol dosage groups compared with formoterol and placebo (see table SV in the supplementary material). Significant differences in 24-hour urinary cortisol were observed between the budesonide/formoterol 320/9 ?g and placebo groups (p = 0.035) at month 6 and between the budesonide/formoterol 320/9 ?g and formoterol groups (p = 0.044) at end of treatment., 24-hour urinary cortisol at 6 months , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,218,1475568,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking ?-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.", Baseline diabetes , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,255,1831737,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.", Secondary school education , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,393,2690844,Significantly decreased,"More patients having undergone a midline incision, reported pain on day one, two and three postoperatively than patients from the transverse group.", Pain on day three after surgery , Midline incision , Transverse incision ,0,
edin,289,1871574,No significant difference,"<td></td><td colspan=""5""><hr></td>", Baseline smoking habits , Usual care , Smoking cessation advice and NRT offered ,0,
edin,473,2847809,Significantly increased,First hemodialysis from newly created AVF in clopidogrel group was significantly more successful than placebo group (P = 0.008)., First hemodialysis success , Placebo , Clopidogrel ,0,
edin,228,1475568,No significant difference,"Among these patients, there was no difference in quality of life score in unadjusted and adjusted analyses (difference = -1.6; 95% CI -15, 12); p = 0.81).", Baseline life-quality score , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,275,2375236,Significantly increased,Patients provided with a question prompt sheet asked more questions about prognosis compared with controls and oncologists gave significantly more prognostic information to these patients., Prognosis enquiry , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,401,2690844,No significant difference,"Briefly, one patient in each group developed cardiac complications; 8 and 6 patients developed urinary retention after the midline and transverse incisions, respectively (P = 0.59).", Cardiac complications , Midline incision , Transverse incision ,0,
edin,310,3580134,Significantly increased,Time to discontinuation was significantly (p ? 0.004) prolonged in both budesonide/formoterol groups versus placebo., Time to discontinuation , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,355,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Breathlessness Cough and Sputum Scale improvement , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,287,1871574,No significant difference,"<td></td><td colspan=""5""><hr></td>", Gender , Usual care , Smoking cessation advice and NRT offered ,0,
edin,427,1187893,No significant difference,"<td colspan=""7""><hr></td>", Functional performance improvement , No exercise , Exercise ,0,
edin,290,1871574,No significant difference,"<td></td><td colspan=""5""><hr></td>", Baseline nicotine dependence variables , Usual care , Smoking cessation advice and NRT offered ,0,
edin,391,2690844,Significantly decreased,"More patients having undergone a midline incision, reported pain on day one, two and three postoperatively than patients from the transverse group.", Pain on day one after surgery , Midline incision , Transverse incision ,0,
edin,384,2721929,Significantly increased,"Mean urgency score decreased by 44.8%, 62.2% and 60.2% in the BT, To, and Co groups, respectively, and the improvement was significantly greater in the To and Co groups than in the BT group (p<0.05 for each).", Urgency score improvement , Bladder training only (BT) , Tolterodine only (To) ,0,
edin,259,1831737,No significant difference,No evidence was found for reduced incidence of self-reported STI symptoms or high-risk sexual behaviour in the intervention communities., Self-reported STI symptoms , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,407,2690844,Significantly increased,Transverse incisions were found to be significantly shorter than midline incisions and associated with more pleasing appearance., Better cosmetic appearance of the incision as subjectively assessed by patients , Midline incision , Transverse incision ,0,
edin,226,1475568,Significantly increased,"Heart failure related knowledge improved more in the intervention group than in the control group. Mean difference in score improvement was 12 percentage points (95% CI 6, 18; p < 0.001).", Knowledge about heart failure , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,368,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Dyspnoea score improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,611,5577662,Significantly decreased,"<td colspan=""5"">Week 8</td>", percentage changes in area ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) ", receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ,0,
edin,571,5602855,No significant difference,The EQ-5D-3L summary index is shown in Fig.Â 2. No significant change could be observed in the anxiety/depression dimension of the EQ-5D-3L system either in those with good (pÂ =Â 0.26) or inadequate (pÂ =Â 0.71) motivation/capability during the three years of follow-up., Quality of life , inadequate motivation/capability , good motivation/capability ,0,
edin,578,4577567,Significantly decreased,"Kinematic parameters measured before and after the 3-week training in RWM showed increased stride length (4.54%; p<0.0001) and contact time (4.58%; p<0.001); inversely, a decreased stride frequency (4.44%; p<0.0001) and internal work (7.09%; p<0.05) were found.,In RWF the effect of the training showed a decrease in stride length (1.18%; p<0.0001) and contact time (<1%; p<0.0001) with respect to baseline conditions and an increased stride frequency and internal work of 1.19% (p<0.0001).", internal work , free stride frequency , stride frequency manipulation ,0,
edin,495,2253708,No significant difference,"<th colspan=""1"" rowspan=""1""></th><th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""3"" rowspan=""1""><hr></th><th align=""left"" colspan=""3"" rowspan=""1""><hr></th><th align=""left"" colspan=""3"" rowspan=""1""><hr></th>", 7-day point prevalence abstinence , Practitioner-delivered brief advice , Tailored letters ,0,
edin,619,4139977,No significant difference,Improvement in bowel habit was observed in 33.3% of the probiotic and 36.5% of the placebo group (P = 0.910)., Improvement in bowel habit ," similar placebo, twice daily after a meal for 14 consecutive days "," receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles ",0,
edin,608,5577662,Significantly increased,"<td colspan=""5"">Week 8</td>,<td colspan=""5"">Week 8</td>", percentage changes in area ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) "," receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ",0,
edin,595,4819709,Significantly increased,"UGFS was superior to EVLA in terms of return to fullâ??time work (hazard ratio 1Â·43, 95 per cent c.i. 1Â·11 to 1Â·85),", Full return to normal work/employment , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,593,4819709,No significant difference,The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were â??having a bath or showerâ?? and â??wearing clothes that show the legsâ??., Wearing clothes that show the legs , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,551,125315,No significant difference,"<td></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td>", The median stay in hospital , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
edin,617,5062234,Significantly decreased,"The visual analog scale scores at rest and on coughing were significantly higher in the local infiltration group in the immediate postoperative period (P = 0.034 and P = 0.007, respectively).", The visual analog scale scores at rest and on coughing , local anesthetic infiltration of the port site. , Transversus abdominis plane block with 0.375% ropivacaine  ,0,
edin,544,2666722,Invalid Prompt,, the risk of SARS infection , health care workers without IgG against Severe acute respiratory syndrome , health care workers with IgG against Severe acute respiratory syndrome ,1, I was not able to find any connection in text between health care workers with IgG against Severe acute respiratory syndrome and the risk of SARS infection. 
edin,556,4785315,Significantly decreased,"The prespecified comparison for women with two or more social risk factors showed a statistically significant reduction in mean EPDS (MD â??0.79 (95% CI â??1.56 to â??0.02) p=0.05), although no significant differences were seen in the mean EPDS (mean difference (MD) â??0.59 (95% CI â??1.24 to 0.06)) for all the women recruited.", Postnatal depression (Edinburgh Postnatal Depression Scale17 EPDS) , standard maternity care ," additional lay support (in this instance Pregnancy Outreach Workers, POWs) ",0,
edin,519,1261533,Significantly decreased,"The mean (SD) decrease in haematocrit value at day seven from baseline was greater in the group receiving MAS3 than in the ALN group: 9.3% (SD,11.5%; 95% CI, 7.7% to 10.9%) compared with 6.7% (SD, 11.4%; 95% CI, 5.1 to 8.3%) respectively (P = 0.023).", Decrease in haematocrit level at day 7 , Mefloquine-artesunate , Artemether-lumefantrine ,0,
edin,620,4139977,No significant difference,"With regard to QOL, an improvement was observed in the probiotic (P = 0.008), but not in the placebo group (P = 0.175); though, there was no significant difference between the two groups in this regard (P = 0.372), Table 2.", quality-of-life  ," similar placebo, twice daily after a meal for 14 consecutive days "," receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles ",0,
edin,583,4819709,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Bending the legs without discomfort</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">3Â·0</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·6</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">1Â·38 (1Â·14, 1Â·67)</td>,Participants randomized to UGFS recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â?? 2 ).", Bending the legs without discomfort , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,599,4819709,Significantly decreased,"Return to â??walking short distances without discomfortâ??, â??walking long distancesâ??, â??looking after childrenâ?? and â??full return to normal work/employmentâ?? took longer for the EVLA group than the UGFS group."," walking short distances without discomfort, walking long distances, looking after children, full return to normal work/employment ", Ultrasoundâ??guided foam sclerotherapy , Endovenous laser ablation ,0,
edin,582,3800940,Invalid Prompt,," Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss. ", Godugdha sodhit Langali moola with honey for external application , Gomutra sodhit Langali moola with honey for external application ,1, Required info can't be found in abstract and there are no other sections for this article. 
edin,560,2888205,Significantly decreased,"<th></th><th colspan=""6""><hr></th>", pain , fibromyalgia (FM) education control (FME) group - received information and support ," lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week ",0,
edin,485,2806484,No significant difference,"184 (24%) patients having home and 145 (27%) facility care either had virological failure, were lost to follow-up, or withdrew from the trial (adjusted rate ratio [RR] 0Â·88, 95% CI 0Â·70â??1Â·10).", Virological failure , Facility-based HIV-care strategy , Home-based HIV-care strategy ,0,
edin,500,2956883,No significant difference,"Gel efficacy against HIV-1 transmission did not differ between centres (p=0Â·19 for interaction), or between consistent (HR 0Â·97, 95% CI 0Â·87â??1Â·35, p=0Â·87) and inconsistent (1Â·17, 0Â·42â??1Â·72, p=0Â·42) gel users (p=0Â·47 for interaction).", Gel efficacy in consistent gel users , Placebo gel , 0Â·5% PRO2000 gel ,0,
edin,561,2888205,No significant difference,"<th></th><th colspan=""6""><hr></th>", six-minute walk test , fibromyalgia (FM) education control (FME) group - received information and support ," lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week ",0,
edin,534,3198285,Significantly decreased,The LGI group achieved a modestly lower GI than the HF group (mean Â± SEM 47 Â± 1 vs. 53 Â± 1; P < 0.001)., lowâ??glycemic index , high-fiber moderate-GI diet (HF) (target glycemic index GI ~60) , lowâ??glycemic index diet (target glycemic index [GI] ~50) ,0,
edin,502,2956883,No significant difference,No deaths or serious adverse events were regarded as related to study gels., Adverse events , Placebo gel , PRO2000 gels ,0,
edin,589,4819709,No significant difference,The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were â??having a bath or showerâ?? and â??wearing clothes that show the legsâ??., Having a bath or shower , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,601,2891743,Significantly increased,"<td colspan=""4""><hr></td>", transurethral resection (TUR) syndrome , glucose 5% solution , glycine 1.5% solution as irrigating fluid ,0,
edin,510,1964758,Significantly increased,"<td colspan=""4""><hr></td>", 8-year survivorship in patients with osteoarthritis , BioModularÂ® shoulder prosthesis , Initial Nottingham TSR design prosthesis ,0,
edin,615,5062234,No significant difference,The 24 h morphine requirement (mean Â± standard deviation) was 34.57 Â± 14.64 mg in TAP group and 32.76 Â± 14.34 mg in local infiltration group (P = 0.688)., The 24 h morphine requirement , local anesthetic infiltration of the port site. , Transversus abdominis plane block with 0.375% ropivacaine  ,0,
edin,602,2891743,Significantly increased,"<td colspan=""4""><hr></td>", transurethral resection (TUR) syndrome , normal saline 0.9% solution , glycine 1.5% solution as irrigating fluid ,0,
edin,512,2829413,Significantly decreased,"After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 Â± 11.38 vs. - 30.07 Â± 10.46%, p < 0.001), LDL-C (48.04 Â± 14.45 vs. 39.52 Â± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 Â± 13.15 vs. - 35.52 Â± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 Â± 18.85 vs. - 32.57 Â± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.", Levels of LDL cholesterol after 6 weeks of treatment , Atorvastatin , Rosuvastatin ,0,
edin,610,5577662,Significantly increased,"<td colspan=""5"">Week 8</td>", global assessment of improvement ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) "," receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ",0,
edin,572,5602855,No significant difference,No statistically significant changes were observed either in the number of visits to the municipal primary healthcare centre (pÂ =Â 0.39) or to special healthcare outpatient clinics (pÂ =Â 0.072) during the follow-up., Health care burden , inadequate motivation/capability , good motivation/capability ,0,
edin,522,1261533,Significantly increased,"Of 452 patients, 119 (26.3%) had P. vivax parasitaemia detected during follow up. There were significantly fewer cases of vivax malaria in the MAS3 group (29 of 227) than in the ALN group (90 of 225) (P < 0.001).", P. vivax parasitaemia diagnosed during follow up , Mefloquine-artesunate , Artemether-lumefantrine ,0,
edin,531,2364680,No significant difference,Fifteen of 380 women (3.9%) developed a wound problem; six had scalpel and nine had electrosurgical subcutaneous incisions (P = 0.4)., wound problem , opening subcutaneous tissues with scalpel , opening subcutaneous tissues with electrocautery ,0,
edin,491,2363351,No significant difference,"Three-year overall survival was 58% and 74% accordingly (n.s., median not yet reached).", Overall survival at 3 years , Cisplatin and Cyclophosphamide ," Cisplatin and Cyclophosphamide, plus subcutaneous IFN-Î³  ",0,
edin,536,3198285,No significant difference,"Table 4
Pregnancy outcomes by diet group,<td align=""left"" colspan=""1"" rowspan=""1"" scope=""row"">Emergency caesarean (%)</td><td align=""center"" colspan=""1"" rowspan=""1"">44</td><td align=""center"" colspan=""1"" rowspan=""1"">20.5</td><td align=""center"" colspan=""1"" rowspan=""1"">44</td><td align=""center"" colspan=""1"" rowspan=""1"">11.6</td><td align=""center"" colspan=""1"" rowspan=""1"">0.263</td>"," Birth weight (kg), Birth weight centile, Small for gestational age, Macrosomia, Infant head circumference, Infant length (cm), Ponderal index (kg/m3), Maternal weight gain (kg), Insulin treatment, Emergency caesarean ", high-fiber moderate-GI diet (HF) (target glycemic index GI ~60) , lowâ??glycemic index diet (target glycemic index [GI] ~50) ,0,
edin,501,2956883,No significant difference,"Gel efficacy against HIV-1 transmission did not differ between centres (p=0Â·19 for interaction), or between consistent (HR 0Â·97, 95% CI 0Â·87â??1Â·35, p=0Â·87) and inconsistent (1Â·17, 0Â·42â??1Â·72, p=0Â·42) gel users (p=0Â·47 for interaction).", Gel efficacy in inconsistent gel users , Placebo gel , 0Â·5% PRO2000 gel ,0,
edin,498,2364533,No significant difference,"When the results were examined without regard to study site, erythromycin had little impact on reducing low birth weight (8% vs. 11%, P = 0.4) or preterm delivery (13% vs. 15%, P = 0.7).", Preterm delivery , Placebo , Erythromycin ,0,
edin,487,2806484,Significantly decreased,"Table 6 shows mean yearly health services cost per patient calculated during 4 years, (including capital and recurrent expenses, and those of the starting phase and subsequent years). A large proportion of the costs were for drugs and staff salaries. The main cause of excess expenditure for the facility-based group was the increased number of contacts with health staffâ??especially with nurses and medical officers. These costs outweighed those of transport for field officers in the home-based group. Patient costs (transport of patient and companion, lunches, child care, and time lost from work) were much higher for the facility-based than for the home-based group (table 6).", Costs for the health service , Facility-based HIV-care strategy , Home-based HIV-care strategy ,0,
edin,609,5577662,Significantly increased,Mean change in nodular consistency and hardness were significantly improved with CCH versus placebo at Weeks 4 and 8 (PÂ â?¤Â 0.0139 for all)., Mean change in nodular consistency and hardness ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) "," receive a dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ",0,
edin,591,4819709,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Doing housework</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">2Â·1</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·5</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">2Â·10 (1Â·72, 2Â·56)</td>,Table 2
Behavioural recovery: ultrasoundâ??guided foam sclerotherapy versus surgery", Doing housework , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,539,2722000,Significantly decreased,"The actuarial rebleeding rate in the prophylactic group was significantly lower than that in the ondemand group (33.9% vs. 62.1%, p=0.004).", rebleeding , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
edin,543,2650992,No significant difference,"Overall, the fibrin glue and control groups were similar in terms of drainage duration, overall drain output, and incidence of seroma.", The mean drainage duration , control group , fibrin glue group (glue sprayed onto the axillary dissection site) ,0,
edin,573,5602855,No significant difference,"At the four monthsâ?? follow-up, 112 (80.6%) subjects with good motivation/capability and 26 (39.4%) with inadequate motivation/capability continued self-assessment of pulse daily.,Irregular pulse findings were not significantly associated with the composite outcome variable (pÂ =Â 0.06), stroke/TIA (pÂ =Â 0.48), pacemaker implantation (pÂ =Â 0.10) or death (pÂ =Â 1.00).,No statistically significant changes were observed either in the number of visits to the municipal primary healthcare centre (pÂ =Â 0.39) or to special healthcare outpatient clinics (pÂ =Â 0.072) during the follow-up.", Self-detected pulse irregularity and outcome events , inadequate motivation/capability , good motivation/capability ,0,
edin,533,3221331,No significant difference,"In the intervention group 7/73 respondents (9.6%) and in the control group 4/81 (4.9%) (P = .3) stated they did not attempt to quit at all, but the majority of respondents in both groups made multiple quit attempts.", did not attempt to quit smoking at all , set a quit date and received a general health video message sent to their phone every 2 weeks. ," an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses. ",0,
edin,314,3580134,Significantly increased,Improvements in pre-dose FEV1 were significantly greater for budesonide/formoterol 320/9 Î¼g compared with formoterol (primary comparison; p = 0.008) and for both budesonide/formoterol dosages compared with placebo (p < 0.001) [figure 3a]., Pre-dose FEV1 improvement , Placebo , Budesonide/formoterol pMDI 320/9 Î¼g ,0,
